Results 51 to 60 of about 59,932 (250)

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters

International Journal of Pharmaceutics: X, 2021
Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels ...
Sawittree Sahakijpijarn, Chaeho Moon, Zachary N. Warnken, Esther Y. Maier, Jennie E. DeVore, Dale J. Christensen, John J. Koleng, Robert O. Williams, III   +7 more
doaj   +1 more source

A brief overview of current drug repurposing approaches for COVID-19 management [PDF]

, 2020
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares, Thomaz, Douglas Vieira   +1 more
core   +2 more sources

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality [PDF]

, 2021
BACKGROUND: Remdesivir is FDA approved for the treatment of hospitalized patients with COVID-19 and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials.
Balani, B., Bernardino, J. I., Boffito, M., Brainard, D. M., Bruno, R., Castagna, A., Chokkalingam, A. P., De Rosa, F. G., De Wit, S., Diaz, G., Diaz-Cuervo, H., Gottlieb, R. L., Goyal, P., Haubrich, R. H., Hu, H., Kim, S. -W., Kurbegov, D., Lee, I. -H., Lin, L., Lye, D. C., Martinez, E., Mullane, K. M., Olender, S. A., Osinusi, A. O., Perez, K. K., Ripamonti, D., Walunas, T. L., Wang, S., Wu, G.   +28 more
core   +1 more source

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

New England Journal of Medicine, 2020
Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.
A. Kalil, T. Patterson, A. Mehta, K. Tomashek, Cameron R. Wolfe, Varduhi Ghazaryan, V. Marconi, G. Ruiz-Palacios, L. Hsieh, S. Kline, V. Tapson, Nicole M. Iovine, M. Jain, D. Sweeney, Hana M. El Sahly, A. Branche, Justino Regalado Pineda, D. Lye, U. Sandkovsky, Anne F. Luetkemeyer, Stuart H. Cohen, R. Finberg, Patrick E H Jackson, B. Taiwo, Catherine I. Paules, H. Arguinchona, P. Goepfert, Neera Ahuja, M. Frank, M. Oh, E. S. Kim, S. Tan, R. Mularski, H. Nielsen, Philip O. Ponce, B. Taylor, L. Larson, N. Rouphael, Youssef Saklawi, Valeria D. Cantos, E. Ko, John J. Engemann, A. Amin, Miki Watanabe, J. Billings, Marie-Carmelle Elie, R. Davey, T. Burgess, J. Ferreira, Michelle Green, M. Makowski, A. Cardoso, S. de Bono, Tyler Bonnett, M. Proschan, G. Deye, Walla Dempsey, S. Nayak, L. Dodd, J. Beigel   +59 more
semanticscholar   +1 more source

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2023
Background Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs.
Chuizhe Chen, Junde Fang, Shu Chen, Mamy Jayne Nelly Rajaofera, Xuemiao Li, Bo Wang, Qianfeng Xia   +6 more
doaj   +1 more source

Effects of Remdesivir on in-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected COVID-19: A Propensity Score-Matched Study

Acta Medica Iranica, 2022
Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi, Ali Ajam, Mahnaz Montazeri, Samira Kafan, Abdolazim Veisizadeh, Morteza Ghoghaei, Sina Kazemian, Arezoo Ahmadi, Fazeleh Majidi, Maryam Moghadasi, Mehdi Kashani, Faezeh Ghasemi, Marzieh Pazoki   +12 more
doaj   +1 more source

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

New England Journal of Medicine, 2020
Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).
J. Goldman, D. Lye, D. Hui, K. Marks, R. Bruno, Rocio Montejano, C. Spinner, M. Galli, M. Ahn, R. Nahass, Y. Chen, Devi SenGupta, R. Hyland, A. Osinusi, H. Cao, C. Blair, Xuelian Wei, A. Gaggar, D. Brainard, W. Towner, J. Muñoz, K. Mullane, F. Marty, K. Tashima, G. Diaz, A. Subramanian   +25 more
semanticscholar   +1 more source

Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters

Pharmaceutics, 2021
Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies, Jörg König, Ute Hofmann, Charlotte Kölz, Martin F. Fromm, Matthias Schwab   +5 more
doaj   +1 more source

Dynamical Fragment Molecular Orbital Interaction Analysis of SARS-CoV‑2 RNA-Dependent RNA Polymerase and Remdesivir. [PDF]

ACS Omega
Miyakawa S, Okuwaki K, Kawashima Y, Handa Y, Furuishi T, Yonemochi E, Kato K, Fukuzawa K.   +7 more
europepmc   +2 more sources

Diagnosis and Management of COVID-19 Disease [PDF]

, 2020
SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham, Dela Cruz, Charles S., Gross, Jane E., Jamil, Shazia, Mark, Nick, Pasnick, Susan   +5 more
core   +1 more source